Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan;98(1):57-67.
doi: 10.1002/cyto.b.21831. Epub 2019 Jun 14.

A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients

Prashant R Tembhare  1 , Papagudi G Subramanian Pg  1 , Sitaram Ghogale  1 , Gaurav Chatterjee  1 , Nikhil V Patkar  1 , Avinash Gupta  1 , Rahul Shukla  1 , Yajamanam Badrinath  1 , Nilesh Deshpande  1 , Gaurav Narula  2 , Pearl Rodrigues  1 , Karishma Girase  1 , Dilshad Dhaliwal  1 , Maya Prasad  2 , Dhanalaxmi Shetty  3 , Shripad Banavali  2 , Sumeet Gujral  4
Affiliations
Free article

A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients

Prashant R Tembhare et al. Cytometry B Clin Cytom. 2020 Jan.
Free article

Abstract

Background: Flow-cytometric minimal residual disease (FC-MRD) monitoring is a well-established risk-stratification factor in B-lymphoblastic leukemia/lymphoma (-B-ALL) and is being considered as a basis for deintensification or escalation in treatment protocols. However, currently practiced standard FC-MRD has limited sensitivity (up to 0.01%) and higher false MRD-negative rate. Hence, a highly sensitive, widely applicable, and easily reproducible FC-MRD assay is needed, which can provide a reliable basis for therapeutic modifications.

Methods: A 10-color high-event analysis FC-MRD assay was studied for the evaluation of MRD status at postinduction, (PI; day-35), postconsolidation, (PC; day-78), and subsequent follow-up time-points (SFU) in bone marrow samples from pediatric B-ALL.

Results: One-thousand MRD samples (PI-62.2%; PC-26.5%; and SFU-11.3%) from 622 childhood B-ALL patients were studied. High-event analysis was performed with median 4,452,000 events (range, 839,000 to 8,866,000 events) and >4 million events in 71% samples. MRD was measurable in 43.2% of PI-samples, in 29.4% PC-samples, and in 32.7% SFU-samples. To simulate comparison with standard FC-MRD, we reanalyzed MRD results gating only first 500,000 and first 1000,000 events in 122 PI-MRD positive samples with MRD levels <0.02%. Of these samples gated for 500,000 events and 1000,000 events, 32% and 21.3% were found to be falsely MRD-negative, respectively.

Conclusions: We report an easily reproducible high-sensitivity 10-color FC-MRD assay with the sensitivity of 2-in-106 (0.0002%). It allowed the detection of low-level MRD in samples, which could have been reported negative using the standard FC-MRD with limited event analysis. Thus, this high-sensitivity MRD-methodology can provide a reliable basis for therapeutic modifications in B-ALL. © 2019 International Clinical Cytometry Society.

Keywords: B-cell acute lymphoblastic leukemia; flow cytometry; high sensitivity; minimal residual disease.

PubMed Disclaimer

References

LITERATURE CITED

    1. Wood BL. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom. 2016;90(1):47-53.
    1. Kim C, Delaney K, McNamara M, Chia V, Romanov V. Cross-sectional physician survey on the use of minimal residual disease testing in the management of pediatric and adult patients with acute lymphoblastic leukemia. Hematology. 2019;24(1):70-78.
    1. Chen J, Xue H, Pan C, Gao Y, Tang Y, Wang J, et al. Cross-sectional physician survey on the use of minimal residual disease testing in the management of pediatric and adult patients with acute lymphoblastic leukemia. Hematol Oncol. 2019;24(1):70-78.
    1. Tembhare PR, Ghogale S, Ghatwai N, Badrinath Y, Kunder N, Patkar NV, Bibi AR, Chatterjee G, Arora B, Narula G, et al. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000. Cytometry B Clin Cytom. 2018;94(1):100-111.
    1. Samra MA, Mahmoud HK, Abdelhamid TM, El Sharkawy NM, Elnahass YH, Elgammal M, et al. The prognostic significance of minimal residual disease in adult Egyptian patients with precursor acute lymphoblastic leukemia. J Egypt Natl Canc Inst. 2013;25(3):135-142.

Publication types

LinkOut - more resources